Show Summary Details
Page of

Neuromuscular blockade 

Neuromuscular blockade
Neuromuscular blockade

A Srivastava

and JM Hunter

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 20 January 2021

Chapter 1 covers neuromuscular blockade, and features papers discussing d-tubocurarine chloride (dtc), pancuronium bromide, quantitative assessment of residual antidepolarizing block, atracurium and its use in patients with no renal function, the pharmacokinetics of atracurium besylate in healthy patients, double burst stimulation (DBS), how residual neuromuscular block is a risk factor for postoperative pulmonary complications, pharyngeal function and airway protection during various degrees of neuromuscular block in the awake state, and the development of an entirely new molecule to reverse the aminosteroidal neuromuscular blocking agent (NMBA), rocuronium, by encapsulation (chelation).

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.